C4 Therapeutics Leadership
Marc A. Cohen
Marc A. Cohen is Co-founder and Executive Chairman of C4 Therapeutics. Marc is also the Co-founder and Chief Executive Officer of Bublup, Inc; Neuro Tennis, Inc.; and COBRO Ventures, Inc.; as well as the Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc., two biotech companies spun out of Dana-Farber Cancer Institute and Harvard University. In addition, Marc was the Co-founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc (Nasdaq: OPNT), a world leader in network and application performance management. OPNET was sold to Riverbed Technology (Nasdaq: RVBD) in December 2012. Marc received a Bachelor of Science in engineering from Harvard University and a Master of Science in electrical engineering from Stanford University. Marc is a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients. Marc enjoys tennis, yoga, and photography, and still hopes to figure out golf one day.
Andy Phillips, PhD
President and Chief Scientific Officer
Andy joined C4 Therapeutics in the role of Chief Scientific Officer in January 2016 and also assumed the position of President in September 2016. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University and a Full Professor of Chemistry and Biochemistry at the University of Colorado. His research and accomplishments have been recognized by a number of awards including the ACS Cope Scholar Award. Andy holds a PhD in Biochemistry and Chemistry from the University of Canterbury.
Andrea joined the C4 Therapeutics team in January 2016, initially as a human resources consultant, and full time in June 2016. At C4T, Andrea leads the Human Resources function which includes; talent acquisition as well as organizational development, employee relations, training and professional development. She also will oversee facilities, lab operations, EHS, IT and office management and internal communications. Prior to joining C4 Therapeutics, Andrea was Chief Human Resources Officer and Vice President of Administration, with overall responsibilities for human resources, facilities, EHS, IT and office management at the New York Genome Center. She holds a BA in International Relations from Tufts University and a Master’s degree in Environmental Health from Boston University. Andrea is happy to be back in the Boston area after four years in NYC.
Isabel Chiu, PhD
Senior Vice President,
Isabel joined C4 Therapeutics in March 2016 as Senior Vice President of Strategic Alliances. Previously, Isabel served as Vice President of Translational Research at AVEO Oncology and most recently at Enumeral Biomedical. In these roles Isabel was responsible for target and biomarker discovery, validation, and preclinical development as well as playing leadership roles in strategic partnerships. She contributed to the development of numerous small molecule and antibody programs in the clinic through external collaborations and internal pipelines. She received her post-doctoral training at Johns Hopkins Medical School, holds a PhD in Biology from MIT, and a Bachelor of Arts in Biochemistry from Brandeis University.
Stew Fisher, PhD
Senior Vice President,
Stew joined C4 Therapeutics in May 2016 as Senior Vice President, Discovery Sciences, responsible for Biophysics, Biochemistry, Structural Biology and Proteomics. Prior to joining C4 Therapeutics, Stew held senior leadership roles at the Broad Institute and previously spent fifteen years at AstraZeneca in roles of increasing responsibility across target validation, drug discovery, and clinical candidate support. Stew started his career at Hoffmann-La Roche after completing an NIH Postdoctoral Fellowship at Harvard Medical School. Stew holds a PhD in Organic Chemistry from the California Institute of Technology and a BA in Chemistry from the University of Vermont.
Chief Financial Officer
Ron Kaiser has over 35 years of Director and executive management experience, serving as a Director, CEO and CFO for public companies and venture-backed portfolio companies in the technology and life sciences industries. Since 1981, he served as CFO during six IPO's or as a CEO for technology companies, and since 2003 as a Director for several public and private companies. He has held executive financial and management roles with Sucampo Pharmaceuticals, OTG Software, Trusted Information Systems, Charmilles Technology Manufacturing Corporation, Leeco Diagnostics, Inc., Somanetics Corporation, and Photon Sources, Inc. Ron is a Principal at Hoffman CFO Consulting, a Certified Board Leadership Fellow of the National Association of Corporate Directors (NACD) and holds dual BA degrees in accounting and multi-disciplinary pre-law from Michigan State University.
Michael Kim, PhD
Vice President of Business Development
Michael joined C4 Therapeutics in August of 2017 as Vice President, Business Development. Most recently, Michael was in the Business Development group at ARIAD Pharmaceuticals where he was responsible for partnering activities in addition to portfolio strategy and alliance management. Michael started his business career as a strategy consultant with Leerink Swann and Company, and progressed to Corporate Strategy and Business Development roles of increasing responsibility at Alkermes, Vertex Pharmaceuticals and FORUM Pharmaceuticals. He received his post-doctoral training as an NIH NRSA Fellow at Harvard Medical School and holds a PhD in Biomedical Engineering from the University of Rochester.
Chris Nasveschuk, PhD
Vice President, Chemistry
Chris joined C4 Therapeutics in February 2016 and serves in the role of Vice President, Chemistry. Most recently Chris was at the Broad Institute, where he led a group of medicinal chemists in projects in the cancer, metabolism, and autophagy disease areas at the Center for the Development of Therapeutics. Prior to the Broad, Dr. Nasveschuk was an integral member of the team at Constellation Pharmaceuticals where he co-invented the EZH2 inhibitor CPI-1205 and helped to discover and develop the BET inhibitor CPI-0610. He holds a PhD in Organic Chemistry from Colorado State University and a BS in Chemistry from Middlebury College.